A post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare diseases potentially the biggest beneficiaries of positive covid legacies – including accelerated development timelines, remote trials and new technologies in genetic and target screening. The report anticipates breakthroughs in multi-modal disease therapies within five years, mRNA platforms to transform many new non-infectious disease treatment options, and huge growth in contract services due to the recent surge in IND applications – with 75 annual FDA approvals expected by 2025. This new analysis combines detailed insights from world leading experts covering perspectives
The post CPhI Report forecasts explosion of contract services growth due to surging INDs and 75 FDA approvals by 2025 appeared first on Pharma Mirror Magazine.
